Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
MTX-211
i
Other names:
MTX-211, MTX211, MTX 211
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Mekanistic Therap
Drug class:
EGFR inhibitor, PI3K inhibitor
Related drugs:
‹
cetuximab (347)
osimertinib (301)
erlotinib (235)
afatinib (227)
gefitinib (194)
panitumumab (123)
lapatinib (107)
neratinib (102)
pyrotinib (79)
brigatinib (50)
icotinib (45)
aumolertinib (39)
amivantamab-vmjw (25)
firmonertinib (14)
mobocertinib (12)
lazertinib (12)
BGB-283 (12)
tarloxotinib bromide (7)
WZ4002 (7)
CH7233163 (6)
H002 (6)
nimotuzumab (6)
BLU-945 (6)
ASLAN001 (6)
BBT-176 (5)
CL-387785 (5)
GB263T (5)
rociletinib (5)
BDTX-189 (5)
AEE788 (4)
BDTX-1535 (4)
BI-4020 (4)
tomuzotuximab (4)
JIN-A02 (4)
TAS2940 (4)
VRN11 (4)
MET306 (4)
EGF816 (4)
AFM24 (3)
BLU-701 (3)
GC-1118A (3)
MCLA-129 (3)
necitumumab (3)
befotertinib (3)
BCA101 (3)
S95026 (3)
ASP8273 (3)
DZD9008 (3)
SZMD4 (3)
AZD3759 (3)
ACE2016 (2)
BI-732 (2)
BLU-451 (2)
Bay846 (2)
ERAS-801 (2)
OBX02-011 (2)
olmutinib (2)
QL1203 (2)
CLN-081 (2)
14aj (1)
ABN202 (1)
ABP 494 (cetuximab biosimilar) (1)
APL-103 (1)
BAY 2927088 (1)
BPI-15086 (1)
BPI-361175 (1)
Compound 6a (1)
abivertinib (1)
KKI04 (1)
PH001 (1)
TAS3351 (1)
TRX-221 (1)
WSD0922 (1)
JMT101 (1)
S-222611 (1)
HMPL-813 (1)
SI-B001 (1)
ASK120067 (1)
SH-1028 (1)
HLX07 (1)
Hemay022 (1)
KD019 (1)
ABT-101 (0)
AC480 (0)
AG1478 (0)
BBT-207 (0)
BC3448 (0)
BMS690514 (0)
CM93 (0)
CUDC-101 (0)
EGF-PTI (0)
DF9001 (0)
DK210 (0)
STI-001 (cetuximab biosimilar) (0)
FHND9041 (0)
HLX35 (0)
HS-10375 (0)
antroquinonol (0)
zalutumumab (0)
IAE0972 (0)
IBI-334 (0)
JANX008 (0)
JNJ-26483327 (0)
JS111 (0)
MM-151 (0)
MP412 (0)
NX-019 (0)
PF-08046052 (0)
PLB1004 (0)
PM1080 (0)
QLH11811 (0)
rindopepimut (0)
SR13668 (0)
SYN004 (0)
Sym013 (0)
TAK-186 (0)
TAK-285 (0)
TAS-121 (0)
TAVO412 (0)
THE-349 (0)
TQ-B3456 (0)
TQB3804 (0)
TY-9591 (0)
U3-1565 (0)
Undisclosed EGFR inhibitor (0)
XZP-5809 (0)
simotinib (0)
ZN-e4 (0)
AST1306 (0)
SY101 (0)
Ami-LC (0)
EMB-01 (0)
cetuximab biosimilar (0)
cipatinib (0)
ABT-806 (0)
MEHD7945A (0)
RO5083945 (0)
TL007 (0)
EMD 72000 (0)
PF-06747775 (0)
JNJ-64041757 (0)
KBP-5209 (0)
SKLB-1028 (0)
AZD8931 (0)
RTB101 (43)
PF-05212384 (31)
RG7440 (27)
chidamide (23)
GDC-0941 (22)
AN2025 (20)
GSK2126458 (17)
MEN1611 (16)
CUDC-907 (8)
rigosertib (7)
LY294002 (7)
PF-04691502 (6)
RP6530 (6)
LY3023414 (5)
GDC-0980 (4)
A66 (3)
enzastaurin (3)
GDC-0084 (3)
PI-103 (2)
AEZS 136 (1)
AEZS-129 (1)
AZD8835 (1)
BAY 1082439 (1)
CB-006-3 (1)
DFN-529 (1)
KU-0060648 (1)
OP-11 (1)
SB02024 (1)
SRX3262 (1)
SAR245408 (1)
CBL0102 (1)
ASN003 (0)
AUM302 (0)
BGT226 (0)
DS-7423 (0)
ETP-47187 (0)
GDC-0349 (0)
GSK1059615 (0)
HEC68498 (0)
IBL-202 (0)
IBL-301 (0)
PIK-75 (0)
SAR260301 (0)
SF1126 (0)
SF2523 (0)
SF2535 (0)
SL-901 (0)
SRX3177 (0)
TG 100-115 (0)
TOP216 (0)
VCD-597 (0)
VS-5584 (0)
WYE-125132 (0)
PQR309 (0)
NSC311152 (0)
inhibitors of the PI3K/AKT/mTOR pathway (0)
VT-11CR (0)
PX 866 (0)
SAR245409 (0)
cetuximab (347)
osimertinib (301)
erlotinib (235)
afatinib (227)
gefitinib (194)
panitumumab (123)
lapatinib (107)
neratinib (102)
pyrotinib (79)
brigatinib (50)
icotinib (45)
aumolertinib (39)
amivantamab-vmjw (25)
firmonertinib (14)
mobocertinib (12)
lazertinib (12)
BGB-283 (12)
tarloxotinib bromide (7)
WZ4002 (7)
CH7233163 (6)
H002 (6)
nimotuzumab (6)
BLU-945 (6)
ASLAN001 (6)
BBT-176 (5)
CL-387785 (5)
GB263T (5)
rociletinib (5)
BDTX-189 (5)
AEE788 (4)
BDTX-1535 (4)
BI-4020 (4)
tomuzotuximab (4)
JIN-A02 (4)
TAS2940 (4)
VRN11 (4)
MET306 (4)
EGF816 (4)
AFM24 (3)
BLU-701 (3)
GC-1118A (3)
MCLA-129 (3)
necitumumab (3)
befotertinib (3)
BCA101 (3)
S95026 (3)
ASP8273 (3)
DZD9008 (3)
SZMD4 (3)
AZD3759 (3)
ACE2016 (2)
BI-732 (2)
BLU-451 (2)
Bay846 (2)
ERAS-801 (2)
OBX02-011 (2)
olmutinib (2)
QL1203 (2)
CLN-081 (2)
14aj (1)
ABN202 (1)
ABP 494 (cetuximab biosimilar) (1)
APL-103 (1)
BAY 2927088 (1)
BPI-15086 (1)
BPI-361175 (1)
Compound 6a (1)
abivertinib (1)
KKI04 (1)
PH001 (1)
TAS3351 (1)
TRX-221 (1)
WSD0922 (1)
JMT101 (1)
S-222611 (1)
HMPL-813 (1)
SI-B001 (1)
ASK120067 (1)
SH-1028 (1)
HLX07 (1)
Hemay022 (1)
KD019 (1)
ABT-101 (0)
AC480 (0)
AG1478 (0)
BBT-207 (0)
BC3448 (0)
BMS690514 (0)
CM93 (0)
CUDC-101 (0)
EGF-PTI (0)
DF9001 (0)
DK210 (0)
STI-001 (cetuximab biosimilar) (0)
FHND9041 (0)
HLX35 (0)
HS-10375 (0)
antroquinonol (0)
zalutumumab (0)
IAE0972 (0)
IBI-334 (0)
JANX008 (0)
JNJ-26483327 (0)
JS111 (0)
MM-151 (0)
MP412 (0)
NX-019 (0)
PF-08046052 (0)
PLB1004 (0)
PM1080 (0)
QLH11811 (0)
rindopepimut (0)
SR13668 (0)
SYN004 (0)
Sym013 (0)
TAK-186 (0)
TAK-285 (0)
TAS-121 (0)
TAVO412 (0)
THE-349 (0)
TQ-B3456 (0)
TQB3804 (0)
TY-9591 (0)
U3-1565 (0)
Undisclosed EGFR inhibitor (0)
XZP-5809 (0)
simotinib (0)
ZN-e4 (0)
AST1306 (0)
SY101 (0)
Ami-LC (0)
EMB-01 (0)
cetuximab biosimilar (0)
cipatinib (0)
ABT-806 (0)
MEHD7945A (0)
RO5083945 (0)
TL007 (0)
EMD 72000 (0)
PF-06747775 (0)
JNJ-64041757 (0)
KBP-5209 (0)
SKLB-1028 (0)
AZD8931 (0)
RTB101 (43)
PF-05212384 (31)
RG7440 (27)
chidamide (23)
GDC-0941 (22)
AN2025 (20)
GSK2126458 (17)
MEN1611 (16)
CUDC-907 (8)
rigosertib (7)
LY294002 (7)
PF-04691502 (6)
RP6530 (6)
LY3023414 (5)
GDC-0980 (4)
A66 (3)
enzastaurin (3)
GDC-0084 (3)
PI-103 (2)
AEZS 136 (1)
AEZS-129 (1)
AZD8835 (1)
BAY 1082439 (1)
CB-006-3 (1)
DFN-529 (1)
KU-0060648 (1)
OP-11 (1)
SB02024 (1)
SRX3262 (1)
SAR245408 (1)
CBL0102 (1)
ASN003 (0)
AUM302 (0)
BGT226 (0)
DS-7423 (0)
ETP-47187 (0)
GDC-0349 (0)
GSK1059615 (0)
HEC68498 (0)
IBL-202 (0)
IBL-301 (0)
PIK-75 (0)
SAR260301 (0)
SF1126 (0)
SF2523 (0)
SF2535 (0)
SL-901 (0)
SRX3177 (0)
TG 100-115 (0)
TOP216 (0)
VCD-597 (0)
VS-5584 (0)
WYE-125132 (0)
PQR309 (0)
NSC311152 (0)
inhibitors of the PI3K/AKT/mTOR pathway (0)
VT-11CR (0)
PX 866 (0)
SAR245409 (0)
›
Associations
News
Trials
Filter by
Latest
1year
MTX-211 Inhibits GSH Synthesis through Keap1/NRF2/GCLM Axis and Exerts Antitumor Effects in Bladder Cancer. (PubMed, Int J Mol Sci)
This study provided evidence that MTX-211 effectively inhibited BLCA cell proliferation via depleting GSH levels through Keap1/NRF2/GCLM signaling pathway. Thus, MTX-211 could be a promising therapeutic agent for cancer.
1 year ago
Journal
|
KEAP1 (Kelch Like ECH Associated Protein 1)
|
MTX-211
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login